HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Emir, S Articles by Varan, A Search for Related Content PubMed PubMed Citation Articles by Emir, S Articles by Varan, A

Varicella vaccination in children with lymphoma and solid tumours

V Köseolu

¹ Department of Pediatric Oncology, SB Ankara Dkap Children’s Training and Research Hospital, Ankara, Turkey
² Department of Pediatric Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
³ Department of Pediatric Oncology, Military Medical Academy, Ankara, Turkey
⁴ Department of Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
⁵ Department of Pediatric Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Correspondence to:
Correspondence to:
S Emir
63. Sokak, 16/7 Emek, Ankara 6510, Turkey; emirs{at}ttnet.net.tr

Background: Varicella infection can be a severe disease, especially in immunosuppressed patients. Here, experience with live varicella vaccine to prevent varicella infection is reported in children who were undergoing treatment for lymphoma and solid tumours.

Methods: 40 children, aged between 12 months and 15 years with no clinical history of varicella, were vaccinated with live varicella vaccine. All received two doses of the vaccine subcutaneously 4 weeks apart. Serum samples were taken before the first dose and 6 weeks after the second dose of vaccine.

Results: Before vaccination, 32 patients were seronegative for varicella and eight were seropositive. Seroconversion was observed 6 weeks after the second dose in 24 of the 32 (75%) seronegative children. In 4 of 8 previously seropositive patients, antibody titres increased after immunisation. Zoster infection occurred 5 weeks after the second dose of vaccine in only one previously seronegative child. 7 children, who had responded to the vaccine, have been exposed to varicella in their families or in school without contracting clinical disease.

Conclusion: Although the small number of patients in our group prevents us from drawing definitive conclusions, the varicella vaccine seems to be well tolerated and can be administered to children with lymphoma and solid tumours undergoing treatment.

Keywords: varicella vaccination; childhood cancer; lymphoma; solid tumour; and children